Backward Masking Tasks to Decipher Impaired Input-Output Connections in MS @7T

NCT ID: NCT05377671

Last Updated: 2022-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-13

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. People with MS frequently suffer from cognitive and visual impairment. Moreover, patients rank cognition and vision as two of the three most valuable bodily functions, in addition to mobility. Here the investigator use the established backward masking paradigm to study structural and functional alteration at the sub-milimeter scale in ultra-high field MRI in order to decipher the different input-output loops associated with the preservation and alteration of cognition in MS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To identify abnormalities in mesoscale input and output connectivity at structural and functional levels that differ between patients with and without cognitive impairment. To address this objective, the investigator will analyse and compare functional activations in the primary visual cortex and task-associated regions in our previous studies. Secondary objectives: To develop, improve and validate multimodal laminar imaging at ultra-high field strength (7T) in comparison to control subjects available in our database to identify and quantify focal impairment in MS.

This is a cross-sectional study. 40 patients (20 patients with a cognitive deficit at least 2 SD below the norm and 20 patients without cognitive impairment) will be explored by multimodal ultra-high field (7T) MRI. The protocol included task, resting FMRI (functional connectivity), diffusion tensor (structural connectivity) and anatomical sequences (lesions and atrophy). In addition, the investigator will analyse standard clinical assessments including a neuropsychological examination. To understand the mechanisms underlying neurodegeneration and adaptation, it is important to contrast physiological and pathological alterations. In addition to comparing cognitively preserved and cognitively impaired patients, the investigator aim to compare our participants to a representative normative dataset available in our database of healthy individuals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Difference in Regional Brain Activity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

40 patients (20 patients with a cognitive deficit at least 2 SD below the norm and 20 patients without cognitive impairment) will be explored by multimodal ultra-high field (7T) MRI
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cognitive deficit group

All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Group Type EXPERIMENTAL

IRM multimodale a ultra-haute camp

Intervention Type DIAGNOSTIC_TEST

The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Without cognitive group

All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Group Type EXPERIMENTAL

IRM multimodale a ultra-haute camp

Intervention Type DIAGNOSTIC_TEST

The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IRM multimodale a ultra-haute camp

The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (\>= 18 years of age) with MS defined according to the McDonald criteria 2017 (Thompson et al., 2018)
* For the group of patients without cognitive impairment: SDMT or PASAT \>=0 (based previous clinical assessments)
* For the group of patients with cognitive impairment: SD SDMT or PASAT \<= -1.5 (based based on previous clinical assessments) (Parmenter et al., 2007)
* Person without uncontrolled systemic disease such as cancer, autoimmune disease, liver failure, severe or untreated hypertension, conduction conduction disorder or severe rhythm disorder
* No one with chronic psychiatric illness, severe dementia syndrome demented syndrome.
* No contraindication to MRI examination (claustrophobia, metallic foreign bodies, pacemakers),
* A person with social security coverage,
* Person having read, understood and signed an informed consent after information

Exclusion Criteria

* Pregnant women
* Other inflammatory demyelinating diseases of the CNS
* Usual contraindications for an MRI examination: claustrophobia, metallic foreign bodies pacemakers, severe renal insufficiency.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François CREMIEUX

Role: STUDY_DIRECTOR

ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE

Jan-Patrick STELLMANN

Role: PRINCIPAL_INVESTIGATOR

ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assistance Publique Hopitaux Marseille

Marseille, Bouches Du Rhône, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jan-Patrick STELLMANN

Role: CONTACT

06.46.28.97.89

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexandra GIULIANI

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-32

Identifier Type: OTHER

Identifier Source: secondary_id

2022-A00174-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Attentional Control
NCT03872999 COMPLETED NA